Key Takeaways:
Parabilis Medicines, a clinical-stage biotech developing peptide drugs for hard-to-reach cellular targets, raised $670M in an upsized Nasdaq IPO that values the company at about $2.3B.
"The upsize is another strong signal that the biotech IPO pipeline is much healthier than it was last year," Lukas Muehlbauer, an associate at IPOX Research, said. "Parabilis stands out by bringing a lot of credibility to the table with the Regeneron partnership."
The Cambridge, Massachusetts-based company sold 33.5M shares at $20 each, above its initial $17-to-$19 range and up from the 25M shares it first planned. Underwriters have a 30-day option to buy an additional 5.025M shares. Parabilis, formerly known as Fog Pharmaceuticals, has raised more than $800M from investors including ARCH Venture Partners, Fidelity Investments, GV and RA Capital since its 2015 founding by Harvard professor Greg Verdine.
The strong pricing signals that institutional investors are willing to back well-capitalized biotechs with strategic partnerships, even as the sector remains selective following a choppy 2025 for listings. Regeneron's $75M private placement and a separate collaboration worth up to $2.2B in milestone payments provide external validation of Parabilis' "Helicon" platform, which engineers peptide medicines to reach targets inside cells — a class of proteins long considered undruggable by conventional biologics.
The company's lead candidate, zolucatetide, is being evaluated in multiple solid-tumor trials with more than 150 patients dosed to date. Parabilis plans to expand into other therapeutic areas beyond oncology, though it has not disclosed a specific timeline.
The Regeneron partnership, announced last month, covers the development of new treatments for hard-to-reach diseases using Parabilis' platform. The deal structure — a $75M equity investment alongside milestone payments that could total $2.2B — mirrors a pattern seen in recent biotech IPOs where strategic pharma backing helps de-risk early-stage science for public market investors.
Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities and LifeSci Capital are the underwriters. Parabilis is expected to begin trading on the Nasdaq under the symbol PBLS on Wednesday.
Parabilis' IPO comes as the biotech IPO market shows signs of recovery after a volatile 2025. Well-received listings from Kailera and Veradermics have encouraged more drug developers to test public market appetite. However, aftermarket performance has been skewed toward larger, better-backed deals, meaning investors are being selective. Parabilis' more than $800M in pre-IPO funding and Regeneron's strategic endorsement position it among the better-capitalized entrants, but as a pre-revenue clinical-stage company with no approved products, its valuation will depend on clinical data readouts from its ongoing zolucatetide trials.
This article is for informational purposes only and does not constitute investment advice.
